CR20210376A - COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY - Google Patents

COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY

Info

Publication number
CR20210376A
CR20210376A CR20210376A CR20210376A CR20210376A CR 20210376 A CR20210376 A CR 20210376A CR 20210376 A CR20210376 A CR 20210376A CR 20210376 A CR20210376 A CR 20210376A CR 20210376 A CR20210376 A CR 20210376A
Authority
CR
Costa Rica
Prior art keywords
treatment
antitrypsin deficiency
compounds
derivatives
a1ad
Prior art date
Application number
CR20210376A
Other languages
Spanish (es)
Inventor
James Andrew Huntington
David John Fox
Nigel Ramsden
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Publication of CR20210376A publication Critical patent/CR20210376A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of α1-antitrypsin deficiency (A1AD or AATD).
CR20210376A 2018-12-14 2019-12-13 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY CR20210376A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820450.3A GB201820450D0 (en) 2018-12-14 2018-12-14 Compound and its use for the treatment of alpha1-antitryspin deficiency
PCT/GB2019/053552 WO2020120992A1 (en) 2018-12-14 2019-12-13 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
CR20210376A true CR20210376A (en) 2021-10-18

Family

ID=65147137

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210376A CR20210376A (en) 2018-12-14 2019-12-13 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY

Country Status (21)

Country Link
US (2) US11312689B2 (en)
EP (1) EP3894393B8 (en)
JP (1) JP2022515372A (en)
KR (1) KR20210104080A (en)
CN (1) CN113227057A (en)
AU (1) AU2019398520A1 (en)
BR (1) BR112021011477A2 (en)
CA (1) CA3122658A1 (en)
CO (1) CO2021009083A2 (en)
CR (1) CR20210376A (en)
EA (1) EA202191239A1 (en)
EC (1) ECSP21051825A (en)
GB (1) GB201820450D0 (en)
IL (1) IL283938A (en)
MA (1) MA54456A (en)
MX (1) MX2021006884A (en)
NI (1) NI202100047A (en)
PE (1) PE20211789A1 (en)
SG (1) SG11202105878WA (en)
WO (1) WO2020120992A1 (en)
ZA (1) ZA202103977B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB202009069D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Process
GB202009074D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Compound
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108542D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108543D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052034A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US6656912B2 (en) * 2000-01-20 2003-12-02 Washington University In St. Louis Methods to treat α1-antitrypsin deficiency
US20070167621A1 (en) * 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
EP1735319B1 (en) * 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
CN101224207A (en) * 2007-10-12 2008-07-23 中国科学院上海有机化学研究所 Medicine for inducing autophagy and treating disease caused by wrong unfolded protein aggregation, and filtration method thereof
MX2010006033A (en) * 2007-12-20 2010-07-16 Bayer Schering Pharma Ag 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof.
EP2776407A1 (en) * 2011-11-08 2014-09-17 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
KR20140088556A (en) * 2011-11-11 2014-07-10 화이자 인코포레이티드 N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
US20140221335A1 (en) * 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016031987A1 (en) * 2014-08-29 2016-03-03 国立大学法人東京大学 Pyrimidinone derivative having autotaxin-inhibitory activity
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918413D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB202009069D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Process
GB2612007A (en) * 2021-06-15 2023-04-26 Z Factor Ltd Compounds
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Also Published As

Publication number Publication date
WO2020120992A1 (en) 2020-06-18
CA3122658A1 (en) 2020-06-18
US11312689B2 (en) 2022-04-26
EP3894393A1 (en) 2021-10-20
NI202100047A (en) 2021-08-31
KR20210104080A (en) 2021-08-24
EA202191239A1 (en) 2021-09-21
US20210332015A1 (en) 2021-10-28
ECSP21051825A (en) 2021-11-18
PE20211789A1 (en) 2021-09-09
MX2021006884A (en) 2021-09-14
ZA202103977B (en) 2022-10-26
GB201820450D0 (en) 2019-01-30
EP3894393B8 (en) 2023-02-15
MA54456A (en) 2022-03-23
AU2019398520A1 (en) 2021-07-01
EP3894393B1 (en) 2022-12-21
IL283938A (en) 2021-07-29
US20220274932A1 (en) 2022-09-01
CO2021009083A2 (en) 2021-07-30
BR112021011477A2 (en) 2021-08-31
CN113227057A (en) 2021-08-06
JP2022515372A (en) 2022-02-18
SG11202105878WA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CR20210376A (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
MX2021004110A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n' -(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl] ethane-1,2-diamine.
CY1123810T1 (en) TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS KALLIKREIN INHIBITORS IN HUMAN PLASMA
MX2021004639A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors.
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
CY1124907T1 (en) KALLIKREIN INHIBITORS IN HUMAN PLASMA
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2021015770A (en) Macrocyclic inhibitors of mcl-1.
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
PH12017501668A1 (en) Bace1 inhibitors
MX2022001261A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
MX2022006180A (en) Macrocyclic sulfonyl derivatives as mcl-1 inhibitors.
MX2022006179A (en) Macrocyclic indole derivatives as mcl-1 inhibitors.
MX2022001266A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
PL424452A1 (en) Inhibitors of inactive endopeptidase (NEP) and human soluble endopeptidase (hSEP) for prevention and treatment of eye diseases
MX2021012146A (en) Vaginal tablet formulation.
MX2022001271A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
MX2019014773A (en) Ccl2 inhibitors.
EA201791798A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING N- (3,5-DIMETOXIPHENYL) -N '- (1-METHYLETHYL) -N- [3- (1-METHYL-1H-PYRAZOL-4-IL) CHINOXALIN-6-IL] ETAN-1 , 2-DIAMOND